PARIS--(BUSINESS WIRE)--Sorin Group (MIL:SRN) announced today the first inclusion of a patient in the Clepsydra clinical trial. The study will investigate the sensitivity to changes in heart failure status of PhD™, a unique diagnostic feature using the dual sensor technology of minute ventilation and accelerometer to monitor patient’s breathing and activity levels every day. The algorithm aims to provide physicians with both trends and indicators in order to highlight sustained changes in overall health status that could relate to heart failure (HF) evolution.
